Loading...
Found 594 results for IU Health Enterprise System
A listing of IU Health Enterprise System medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
M
Monika Fischer, MD
What is the purpose of this study?The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active …
Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
K
Kathy Miller, MD
This is a randomized Phase II study of carboplatin monotherapy vs. carboplatin combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, …
Examining Genetic Ancestry, Allostatic Load and Treatment Completion among Patients with Breast Cancer
T
Tarah Ballinger, MD
The main purpose of this study is to learn more about how genetic ancestry affects treatment completion for patients who are diagnosed with breast cancer. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: …
Abatacept in Immune Checkpoint Inhibitor Myocarditis (ATRIUM)
S
Suparna C. Clasen, MD, MSCE
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden …
Using a Novel Lay Patient Navigation Model to Improve Cascade Testing Rates for Hereditary Cancer Syndromes in Black Patients and Their Family Members
N
Nawal Kassem
The purpose of this study is to improve genetic testing rates in families of Black patients who are found to have a hereditary cancer syndrome. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: …
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
N
Namita Agrawal
The purpose of this study is to examine the feasibility of adding pre-rehabilitation pelvic health physical therapy to standard of care radiation therapy treatment plan for female patients who have been diagnosed with cervical, vaginal, vulvar, uterine, or anal cancer and are a candidate for curative pelvic radiation with external …
Circulating Tumor HPV DNA Driven Adjuvant Treatment Deintensification after Transoral Surgery for HPV-Positive Squamous Cell Carcinoma of the Oropharynx
M
Michael W. Sim, MD
People with Oropharyngeal squamous cell carcinoma (OPSCC) typically receive standard treatment with a combination of chemotherapy, radiation therapy, and surgery. Due to the intensity of standard treatment, survivors may experience unwanted long-term side effects. The goal of this research study is to see if de-intensifying treatment still provides the same, …
A Randomized Phase II Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
S
Samantha Armstrong
What is the purpose of this study?This phase II trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started to other places in the …
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients with Locally Advanced or Metastatic Solid Tumors
G
Greg Durm, MD
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in patients with advanced or metastatic solid tumors. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive …
PSMAcTION: A phase II/III, open-label, international, multi-center, randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy.
N
Nabil Adra, MD
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy.Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is …
Please choose between Voice or SMS based delivery of verification code
or